25I-NBOMe: Difference between revisions
>MDMQualone mNo edit summary |
>MDMQualone mNo edit summary |
||
Line 158: | Line 158: | ||
*'''China''' - As of October 2015 25I-NBOMe is a controlled substance in China.<ref>{{cite web | url=http://www.sfda.gov.cn/WS01/CL0056/130753.html | title=关于印发《非药用类麻醉药品和精神药品列管办法》的通知 | publisher=China Food and Drug Administration | date=27 September 2015 | language=Chinese | accessdate=1 October 2015}}</ref> | *'''China''' - As of October 2015 25I-NBOMe is a controlled substance in China.<ref>{{cite web | url=http://www.sfda.gov.cn/WS01/CL0056/130753.html | title=关于印发《非药用类麻醉药品和精神药品列管办法》的通知 | publisher=China Food and Drug Administration | date=27 September 2015 | language=Chinese | accessdate=1 October 2015}}</ref> | ||
*'''New Zealand:''' 25I-NBOMe is a Schedule 2 controlled substance in New Zealand.<ref>http://www.legislation.govt.nz/act/public/1975/0116/latest/whole.html#DLM436576</ref> | *'''New Zealand:''' 25I-NBOMe is a Schedule 2 controlled substance in New Zealand.<ref>http://www.legislation.govt.nz/act/public/1975/0116/latest/whole.html#DLM436576</ref> | ||
*'''Canada:''' 25I-NBOMe would be considered Schedule III as it is a derivative of 2,5-dimethoxyphenethylamine.<ref>Controlled Drugs and Substances Act (S.C. 1996, c. 19) |http://laws-lois.justice.gc.ca/eng/acts/C-38.8/page-12.html#h-28</ref> | |||
==See also== | ==See also== |